Recent developments in the use of systemic adjuvant therapy for the treatment of breast cancer.

Suppr

超能文献

作者信息

Fisher B, Wickerham D L, Redmond C

机构信息

National Surgical Adjuvant Breast and Bowel Project (NSABP) Headquarters, Pittsburgh, PA 15261.

出版信息

Semin Oncol. 1992 Jun;19(3):263-77.

PMID:1344973

Abstract

摘要

相似文献

Recent developments in the use of systemic adjuvant therapy for the treatment of breast cancer.

Semin Oncol. 1992 Jun;19(3):263-77.

[The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Chemotherapy: the example of clinical studies].[乳腺癌辅助治疗的最佳持续时间：何种证据？化疗：临床研究实例]

Suppl Tumori. 2004 Jul-Aug;3(4):S77-8.

Improved outcomes from dose-dense adjuvant chemotherapy for breast cancer with growth factor support.在生长因子支持下，密集剂量辅助化疗改善乳腺癌治疗效果。

Curr Hematol Rep. 2003 Nov;2(6):451-2.

Post-operative therapy of breast cancer: rationale for adjuvant chemotherapy.

J S C Med Assoc. 1984 Jan;80(1):15-6.

Randomized clinical trials in breast cancer: a tabular summary. Part 1: Primary breast cancer.乳腺癌随机临床试验：表格总结。第1部分：原发性乳腺癌。

Arch Geschwulstforsch. 1986;56(3):211-36.

Evolving concepts in the systemic adjuvant treatment of breast cancer.

Cancer Res. 1992 Apr 15;52(8):2127-37.

High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out.大剂量化疗（HDC）联合自体骨髓移植（ABMT）治疗乳腺癌：尚无定论。

Important Adv Oncol. 1995:201-14.

[Adjuvant therapy of breast cancer without regional metastases].[无区域转移乳腺癌的辅助治疗]

Klin Khir. 1995(5):42-6.

[The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Chemotherapy: what kind of evidence?].[乳腺癌辅助治疗的最佳疗程：何种证据？化疗：何种证据？]

Suppl Tumori. 2004 Jul-Aug;3(4):S79-80.

[Adjuvant therapy in breast cancer].[乳腺癌的辅助治疗]

Vopr Onkol. 2000;46(1):18-27.

引用本文的文献

Comparison of Modified Radical Mastectomy with Quadrantectomy, Axillary Dissection, and Radiation Therapy in Early Breast Cancer in Japaness Women.日本女性早期乳腺癌改良根治术与象限切除术、腋窝清扫术及放射治疗的比较。

Breast Cancer. 1995 Oct 31;2(2):119-125. doi: 10.1007/BF02966950.

Multidisciplinary approach to the treatment of unresectable breast cancer.

World J Surg. 1995 Nov-Dec;19(6):843-6. doi: 10.1007/BF00299781.

Adjuvant therapy of breast cancer.

World J Surg. 1994 Jan-Feb;18(1):112-6. doi: 10.1007/BF00348200.

Present status and potential role of high-dose adjuvant chemotherapy in breast cancer with poor prognosis.高剂量辅助化疗在预后不良乳腺癌中的现状及潜在作用

Arch Gynecol Obstet. 1994;255 Suppl 2:S379-80. doi: 10.1007/BF02389261.

Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.绝经前可切除的淋巴结阳性乳腺癌患者。比较三种辅助治疗方案的随机试验初步结果：FEC 50方案6个周期对比FEC 50方案3个周期对比FEC 75方案3个周期。法国辅助治疗研究组。

Drugs. 1993;45 Suppl 2:38-45. doi: 10.2165/00003495-199300452-00007.

High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.大剂量卡铂、噻替派和环磷酰胺（CTC）联合外周血干细胞支持用于高危乳腺癌辅助治疗的实用方法

Br J Cancer. 1995 Apr;71(4):857-62. doi: 10.1038/bjc.1995.165.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验